Search

Displaying results 2891 - 2900 of 10000 in total
  1. Drug

    Taletrectinib

    go.drugbank.com/drugs/DB18711
    ApprovedInvestigational

    [L53308] Gene fusions involving _ROS1_, a proto-oncogene, have been identified as oncogenic drivers in 1-2% of patients with non-small cell lung cancer (NSCLC), in addition to other cancers at variable … [A274118] Taletrectinib was approved by the US FDA in June 2025 for use in patients with advanced ROS1-positive NSCLC.[L53308,L53523]

  2. Drug

    Tazarotene

    go.drugbank.com/drugs/DB00799
    Approved

    It is a prodrug that is found in topical formulations used in the treatment of various conditons, such as psoriasis, acne, and sun damaged skin (photodamage).

    Categories: Antipsoriatics for Topical Use
  3. Drug

    Cefotetan

    go.drugbank.com/drugs/DB01330
    ApprovedInvestigational

    A semisynthetic cephamycin antibiotic that is administered intravenously or intramuscularly. … The drug is highly resistant to a broad spectrum of beta-lactamases and is active against a wide range of both aerobic and anaerobic gram-positive and gram-negative microorganisms.

    Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic UseSynonyms: (6R,7S)-7-(4-(carbamoylcarboxymethylene)-1,3-dithiethane-2-carboxamido)-7-methoxy-3-(((1-methyl-1H-tetrazol-5- yl)thio)methyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2- carboxylic acid
  4. Drug

    Edoxudine

    go.drugbank.com/drugs/DB13421
    ApprovedWithdrawn

    It was later recognized to be effective in vivo in a preclinical model of keratitis caused by herpes virus. … Edoxudine is a deoxythymidine analog with activity against herpes simplex virus. It is a potent and selective inhibitor of herpes simplex virus type 1 and 2.

  5. Drug

    Berdazimer

    go.drugbank.com/drugs/DB18712
    Approved

    Berdazimer is a polymeric substance consisting of a polysiloxane backbone (Si-O-Si bonds) with covalently bound N-diazeniumdiolate nitric oxide (NO) donors. … [A262960] Berdazimer was previously investigated as a potential treatment for molluscum contagiosum, a viral cutaneous infection mainly affecting children, sexually active adults, and immunocompromised

    Synonyms: Silsesquioxanes, 3-(2-hydroxy-1-methyl-2-nitrosohydrazinyl)propyl 3-(methylamino)propyl, polymers with silicic acid (h4sio4) tetra-et ester, hydroxy-terminated
  6. Drug

    Mavacamten

    go.drugbank.com/drugs/DB14921
    ApprovedInvestigational

    Mavacamten is a myosin inhibitor indicated for the treatment of adults with symptomatic New York Heart Association (NYHA) class II-III obstructive hypertrophic cardiomyopathy (HCM). … [A248440] Mavacamten was also approved by Health Canada in October 2022 and by EMA in July 2023 for the same indication.[L44106,L47471]

  7. Drug

    beta-Hydroxybutyric acid

    go.drugbank.com/drugs/DB16506
    Investigational

    Beta-hydroxybutyrate is being studied in around 230 clinical trials, including NCT06351124 (recruiting for Crohn's disease), NCT05584371 (recruiting for safety and tolerability of exogenous ketosis), NCT04656236 … (completed for type 1 diabetes), and NCT05581043 (completed for type 2 diabetes).

    Categories: Experimental Unapproved Treatments for COVID-19
  8. Drug

    Phenolsulfonphthalein

    go.drugbank.com/drugs/DB13212
    Experimental

    Phenolsulfonphthalein or otherwise called phenol red is a pH indicator commonly used in cell biology laboratories. … Phenolsulfonphthalein is being investigated for use clinically due to its weak estrogen mimicking actions [A174964].

    Categories: Compounds used in a research, industrial, or household setting, Tests for Renal Function and Ureteral Injuries
  9. Drug

    Salicylamide

    go.drugbank.com/drugs/DB08797
    Approved

    Salicylamide is the common name for the substance o-hydroxybenzamide, or amide of salicyl. Salicylamide is a non-prescription drug with analgesic and antipyretic properties. … Salicylamide is used in combination with both aspirin and caffeine in the over-the-counter pain remedies

  10. Drug

    Abametapir

    go.drugbank.com/drugs/DB11932
    Approved

    [A216178] Abametapir was first approved for use in the United States under the brand name Xeglyze on July 27, 2020.[L15163] … The improved ovicidal activity (90-100% _in vitro_) of abemetapir allows for a single administration, in contrast to many other topical treatments, and its novel and relatively non-specific mechanism may